$SGP News
Last published 2h ago
- 2h agoSGPSpyGlass Pharma Reports Third Quarter 2026 Financial Results and Provides Corporate UpdatesGlobeNewswireIRVINE, Calif., Nov. 11, 2026 (GLOBE NEWSWIRE) -- SpyGlass Pharma, Inc. (Nasdaq: SGP) (“SpyGlass Pharma” or “Company”), a late-stage biopharmaceutical company, today reported recent business highlights and financial results for the third quarter ended September 30, 2026.
- 6d agoSGPSpyGlass Pharma to Participate in Upcoming Investor ConferencesGlobeNewswireIRVINE, Calif., Nov. 05, 2026 (GLOBE NEWSWIRE) -- SpyGlass Pharma, Inc. (NASDAQ:SGP) ("SpyGlass Pharma" or "Company"), a late-stage biopharmaceutical company, today announced that members of the
- 3w agoSGPSpyGlass Pharma Announces Positive 4-Year Data From First-in-Human Trial of Its Innovative BIM-IOL SystemGlobeNewswireGroundbreaking 4-year safety and efficacy results: 37% reduction in mean intraocular pressure (IOP) across all dose groups86% of patients remained off all topical IOP-lowering drops90% of patients maintained ≥20/25
- 2mo agoSGPSpyGlass Pharma to Participate in Upcoming Investor ConferencesGlobeNewswireIRVINE, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- SpyGlass Pharma, Inc. (NASDAQ:SGP) ("SpyGlass Pharma" or "Company"), a late-stage biopharmaceutical company, today announced that members of the
- 3mo agoSGPSpyGlass Pharma Reports Second Quarter 2026 Financial Results and Provides Corporate UpdatesGlobeNewswireEnrollment remains on track in the registrational Phase 3 trials of the Bimatoprost Drug Pad-IOL System (BIM-IOL System), with completion of enrollment expected in 2027.Bimatoprost-Drug Ring System (BIM-DRS)
- 4mo agoSGPSpyGlass Pharma Appoints Shannon Treviño as General CounselGlobeNewswireALISO VIEJO, Calif., June 15, 2026 (GLOBE NEWSWIRE) -- SpyGlass Pharma, Inc. (NASDAQ:SGP) (SpyGlass Pharma or Company), a late-stage biopharmaceutical company, today announced the appointment of Shannon Treviño as
- 5mo agoSGPSpyGlass Pharma Appoints Mike Pinder as Vice President, MarketingGlobeNewswireALISO VIEJO, Calif., June 02, 2026 (GLOBE NEWSWIRE) -- SpyGlass Pharma, Inc. (NASDAQ:SGP) (SpyGlass Pharma), a late-stage biopharmaceutical company, today announced the appointment of Mike Pinder as vice president,
- 5mo agoSGPSpyGlass Pharma to Participate in Upcoming Investor ConferencesGlobeNewswireALISO VIEJO, Calif., May 21, 2026 (GLOBE NEWSWIRE) -- SpyGlass Pharma, Inc. (NASDAQ:SGP) ("SpyGlass Pharma" or "Company"), a late-stage biopharmaceutical company, today announced that members of the executive
- 5mo agoSGPSpyGlass Pharma Announces New Add-on Category III CPT Code for Its Innovative BIM-IOL SystemGlobeNewswireALISO VIEJO, Calif., May 18, 2026 (GLOBE NEWSWIRE) -- SpyGlass Pharma, Inc. (NASDAQ:SGP) (SpyGlass Pharma), a late-stage biopharmaceutical company, today announced that the American Medical Association's (AMA)
- 6mo agoSGPSpyGlass Pharma Reports First Quarter 2026 Financial Results and Provides Corporate UpdatesGlobeNewswireEnrollment remains on track in the registrational Phase 3 trials of the Bimatoprost Drug Pad-IOL System (BIM-IOL System), with completion of enrollment expected in 2027.Topline 12-month data from the BIM-IOL System Phase
- 7mo agoSGPSpyGlass Pharma Reports Fourth Quarter and Full Year 2025 Earnings and Provides a Corporate UpdateGlobeNewswireSuccessfully completed Initial Public Offering (IPO) in February 2026, raising $172.5 million and listing on Nasdaq.Reported positive topline 12-month data from Phase 1/2 trial of the Bimatoprost Drug Pad-IOL System
- 8mo agoSGPSpyGlass Pharma Announces Positive Topline 12-Month Phase 1/2 Trial Results for Its Innovative BIM-IOL SystemGlobeNewswire97% of patients who received the BIM-IOL System off all topical IOP-lowering therapy at 12-months100% of BIM-IOL System patients achieved 20/32 or better BCDVA and a mean BCDVA equivalent to 20/20 vision, demonstrating
- 8mo agoSGPSpyGlass Pharma to Participate in the Jefferies Biotech on the Beach SummitGlobeNewswireALISO VIEJO, Calif., March 04, 2026 (GLOBE NEWSWIRE) -- SpyGlass Pharma, Inc. (NASDAQ:SGP) ("SpyGlass Pharma"), a late-stage biopharmaceutical company, today announced that members of the executive management team will
- 9mo agoSGPSpyGlass Pharma Announces Closing of Initial Public Offering and Exercise in Full of the Underwriters' Option to Purchase Additional SharesGlobeNewswireALISO VIEJO, Calif., Feb. 09, 2026 (GLOBE NEWSWIRE) -- SpyGlass Pharma, Inc. (NASDAQ:SGP) ("SpyGlass Pharma"), a late-stage biopharmaceutical company, today announced the closing of its initial public offering of
- 9mo agoSGPSpyGlass Pharma Announces Pricing of Initial Public OfferingGlobeNewswireALISO VIEJO, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- SpyGlass Pharma, Inc. (NASDAQ:SGP) ("SpyGlass Pharma"), a late-stage biopharmaceutical company, today announced the pricing of its initial public offering of